Fagron NV/€FAGR

1D1W1MYTD1Y5YMAX

About Fagron NV

Fagron NV is a pharmaceutical company specializing in pharmaceutical compounding, providing personalized medical solutions to hospitals, pharmacies, clinics, and patients across more than 30 countries. The company operates through three segments: Essentials, offering pharmaceutical raw materials and equipment; Brands, developing innovative compounding concepts and formulations; and Compounding Services, delivering ready-to-use medications from its sterile and non-sterile facilities. Founded in 1990 in Rotterdam, the Netherlands, Fagron has expanded its operations globally, with its registered office in Nazareth, Belgium, and operational headquarters in Rotterdam. The company's strategic focus on innovation and quality has enabled it to establish a significant presence in the pharmaceutical compounding market.
Ticker
€FAGR
Sector
Health
Primary listing
BSE
Employees
4,880
Headquarters
Nazareth, Belgium
Website
www.fagron.com

Fagron NV Metrics

BasicAdvanced
€1.6B
16.86
€1.25
0.38
€0.28
1.33%

Bulls say / Bears say

Fagron delivered 16% H1 revenue growth to €552.5 million, 12.7% adjusted EBITDA growth and 10.8% operating cash-flow growth. It also reiterated its 2026 targets for mid- to high-single-digit organic growth and an adjusted EBITDA margin of about 20%. (Fagron Investors)
The company is showing useful geographic and product diversification: EMEA and Latin America led organic growth, while Latin American Brands and Essentials performed particularly strongly. That reduces reliance on any single market and gives the innovation and Brands strategy room to scale. (Fagron Investors, Fagron Investors)
Fagron completed five acquisitions in the first half, including Amber in Singapore and Malaysia, and said integration was on track. Its stated expectation of stronger second-half profitability, supported by operational improvements and acquisition synergies, offers a potential earnings catalyst if execution continues. (Fagron Investors, Investing.com)
North America-Pacific remains a material weakness. H1 organic growth there was only 0.2% as strong Brands and Essentials performance was offset by lower compounding volumes after GLP-1 revenue normalised and IV-bag availability was limited. (Roic AI, Fagron Investors)
Fagron received an FDA Warning Letter after the Boston facility inspection and had already carried out a limited voluntary Class II recall linked to defective third-party IV bags. Although production continues and no adverse events were reported, remediation and tighter oversight create operational, cost and reputational risk. (Fagron Investors)
Headline growth is more acquisition-led than organic: H1 organic growth was 3.1% at constant exchange rates, while the 19.4% adjusted EBITDA margin was below the roughly 20% full-year target and the 20.3% achieved in 2025. This leaves investors dependent on successful integration and synergies, while recent deals can dilute margins before they mature. (Fagron Investors, Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.

Funds containing Fagron NV

AllEURGBPUSD
Funds
Fund name
Fund size
€FAGR weighting
Xtrackers MSCI Europe Small Cap€DX2J
€3.2B0.11%
Xtrackers MSCI Europe Small Cap£XXSC
£2.8B0.11%
iShares MSCI World Small Cap$WSML
$9B0.01%
iShares MSCI World Small Cap€IUSN
€7.8B0.01%
iShares MSCI World Small Cap£WLDS
£6.7B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.